ORJEMSA Trademark

Trademark Overview


On Wednesday, September 14, 2022, a trademark application was filed for ORJEMSA with the United States Patent and Trademark Office. The USPTO has given the ORJEMSA trademark a serial number of 97591746. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 17, 2025. This trademark is owned by Day One Biopharmaceuticals, Inc.. The ORJEMSA trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations for human use for the treatment of cancer; pharmaceutical preparation for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations and substances for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders; targeted pharmaceutical preparations for use in cancer prevention and treatment; pharmaceutical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, ps...

Medical information services; healthcare services; healthcare services, namely, providing cancer treatment information to physicians, health care professionals, and patients; medical information services, namely, providing information regarding viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders
orjemsa

General Information


Serial Number97591746
Word MarkORJEMSA
Filing DateWednesday, September 14, 2022
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 17, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 21, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment of cancer; pharmaceutical preparation for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations and substances for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders; targeted pharmaceutical preparations for use in cancer prevention and treatment; pharmaceutical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders
Goods and ServicesMedical information services; healthcare services; healthcare services, namely, providing cancer treatment information to physicians, health care professionals, and patients; medical information services, namely, providing information regarding viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 29, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, September 29, 2022
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameDay One Biopharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBrisbane, CA 94005

Party NameDay One Biopharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBrisbane, CA 94005

Trademark Events


Event DateEvent Description
Friday, March 10, 2023NON-FINAL ACTION E-MAILED
Saturday, September 17, 2022NEW APPLICATION ENTERED
Thursday, September 29, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 7, 2023ASSIGNED TO EXAMINER
Friday, March 10, 2023NON-FINAL ACTION WRITTEN
Friday, March 10, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, June 6, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, June 6, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, September 11, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, September 11, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 12, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 2, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, October 10, 2023FINAL REFUSAL WRITTEN
Tuesday, October 10, 2023FINAL REFUSAL E-MAILED
Tuesday, October 10, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, January 2, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, April 4, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 4, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, April 5, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 18, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 1, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 21, 2024PUBLISHED FOR OPPOSITION
Tuesday, May 21, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 16, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, January 10, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, January 10, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 10, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, February 17, 2025ABANDONMENT - NO USE STATEMENT FILED
Monday, February 17, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED